# EVOLVE 1 (NCT07075016)

> Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07075016
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland
- Conditions: Acute Myeloid Leukemia
- Interventions: Venetoclax 400; Placebo
- Enrollment: 227
- Primary outcome: Event-free survival (EFS) in patients with newly diagnosed IDH1-mutated AML ineligible for intensive chemotherapy

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 2
- X threads: 2
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=evolve-1-nct07075016